Inscrição na biblioteca: Guest
Critical Reviews™ in Immunology

Publicou 6 edições por ano

ISSN Imprimir: 1040-8401

ISSN On-line: 2162-6472

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.3 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.6 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00079 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.24 SJR: 0.429 SNIP: 0.287 CiteScore™:: 2.7 H-Index: 81

Indexed in

Botulinum Neurotoxin Vaccines: Past, Present, and Future

Volume 27, Edição 4, 2007, pp. 303-318
DOI: 10.1615/CritRevImmunol.v27.i4.20
Get accessGet access

RESUMO

In the early 1930s, a formalin-inactivated toxoid against botulinum neurotoxin was first tested in humans. In 1965, a pentavalent botulinum toxoid (PBT) received Investigational New Drug (IND) status under the Centers for Disease Control's IND 161 (for at-risk workers), and in 1991 under the United States Army's Office of the Surgeon General IND 3723 (for military deployment). This PBT vaccine has been shown to be safe, with over 20,000 injections given to date, and continues to be used in at-risk individuals. During the past decade, recombinant DNA technology has been employed to develop second-generation vaccines to prevent botulism. Recombinant subunit vaccines utilizing the receptor-binding domains of botulinum neurotoxin (BoNT) have been shown to be safe and efficacious in protecting animal models against BoNT serotypes A, B, C1, D, E, and F. In 2004, the first recombinant subunit vaccine [rBV A/B (Pichia pastoris) vaccine] was tested in humans during a phase I clinical trial. Results from that study demonstrated that the recombinant bivalent vaccine was safe and well tolerated at all dosage levels tested and stimulated serotype-specific neutralizing antibodies among the majority of vaccine recipients.

CITADO POR
  1. Smith Leonard A., Rusnak Janice M., Botulism Vaccines and the Immune Response, in Botulinum Toxin, 2009. Crossref

  2. Naumann Markus, Boo Lee Ming, Ackerman Alan H., Gallagher Conor J., Immunogenicity of botulinum toxins, Journal of Neural Transmission, 120, 2, 2013. Crossref

  3. Zdanovsky Alexey, Zdanovsky Denis, Zdanovskaia Maria, Epitope mapping of botulinum neurotoxins light chains, Toxicon, 60, 7, 2012. Crossref

  4. Pittman Phillip R., Plotkin Stanley A., Biodefense and special pathogen vaccines, in Vaccines, 2013. Crossref

  5. Ma Yao, An Huai-Jie, Wei Xiao-Qi, Xu Qing, Yu Yun-Zhou, Sun Zhi-Wei, Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant, Human Vaccines & Immunotherapeutics, 9, 2, 2013. Crossref

  6. Yu Yun-Zhou, Guo Jin-Peng, An Huai-Jie, Zhang Shu-Ming, Wang Shuang, Yu Wei-Yuan, Sun Zhi-Wei, Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors, Vaccine, 31, 20, 2013. Crossref

  7. Hu Xin, Legler Patricia M., Southall Noel, Maloney David J., Simeonov Anton, Jadhav Ajit, Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening, Journal of Computer-Aided Molecular Design, 28, 7, 2014. Crossref

  8. Shi Xuerong, Garcia Gregory E., Neill Roger J., Gordon Richard K., TCEP treatment reduces proteolytic activity of BoNT/B in human neuronal SHSY-5Y cells, Journal of Cellular Biochemistry, 107, 5, 2009. Crossref

  9. Stahl Andrea M., Adler Michael, Millard Charles B., Gilfillan Lynne, Accelerating botulism therapeutic product development in the Department of Defense, Drug Development Research, 70, 4, 2009. Crossref

  10. Ramasamy S, Liu CQ, Tran H, Gubala A, Gauci P, McAllister J, Vo T, Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents, British Journal of Pharmacology, 161, 4, 2010. Crossref

  11. Böhnel H., Gessler F., Neurotoxigenic Clostridia, in Pathogenesis of Bacterial Infections in Animals, 2010. Crossref

  12. Basiri Mohsen, Mousavi Seyed Latif, Basiri Hossein, Rasooli Iraj, An epitopic approach to designing and characterization of a multiple antigenic polypeptide against Botulinum neurotoxins A and E, World Journal of Microbiology and Biotechnology, 26, 9, 2010. Crossref

  13. Hudacek Andrew W, Al-Saleem Fetweh H, Willet Mallory, Eisemann Travis, Mattis Jeffrey A, Simpson Lance L, Schnell Matthias J, Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo, Molecular Therapy - Methods & Clinical Development, 1, 2014. Crossref

  14. Yu YunZhou, Liu Si, Ma Yao, Gong Zheng-Wei, Wang Shuang, Sun Zhi-Wei, Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors, Human Vaccines & Immunotherapeutics, 10, 7, 2014. Crossref

  15. Yu YunZhou, Shi DanYang, Liu Si, Gong Zheng-Wei, Wang Shuang, Sun ZhiWei, Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system, Human Vaccines & Immunotherapeutics, 11, 2, 2015. Crossref

  16. Rosen Osnat, Feldberg Liron, Gura Sigalit, Zichel Ran, A new peptide substrate for enhanced botulinum neurotoxin type B detection by endopeptidase–liquid chromatography–tandem mass spectrometry/multiple reaction monitoring assay, Analytical Biochemistry, 473, 2015. Crossref

  17. Henkel James S., Tepp William H., Przedpelski Amanda, Fritz Robert B., Johnson Eric A., Barbieri Joseph T., Subunit vaccine efficacy against Botulinum neurotoxin subtypes, Vaccine, 29, 44, 2011. Crossref

  18. Stahl Christina, Unger Lucia, Mazuet Christelle, Popoff Michel, Straub Reto, Frey Joachim, Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D, Vaccine, 27, 41, 2009. Crossref

  19. Yu Yunzhou, Yu Jiyu, Li Na, Wang Shuang, Yu Weiyuan, Sun Zhiwei, Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors, Vaccine, 27, 44, 2009. Crossref

  20. Yu Yun-Zhou, Wang Wen-Bin, Li Na, Wang Shuang, Yu Wei-Yuan, Sun Zhi-Wei, Enhanced potency of individual and bivalent DNA replicon vaccines or conventional DNA vaccines by formulation with aluminum phosphate, Biologicals, 38, 6, 2010. Crossref

  21. Yu Yun-Zhou, Li Na, Zhu Heng-Qi, Wang Rui-Lin, Du Yun, Wang Shuang, Yu Wei-Yuan, Sun Zhi-Wei, The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate, Vaccine, 27, 21, 2009. Crossref

  22. Shearer Jeffry D., Vassar Michelle L., Swiderski William, Metcalfe Karen, Niemuth Nancy, Henderson Ian, Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B), Vaccine, 28, 45, 2010. Crossref

  23. Masuyer Geoffrey, Thiyagarajan Nethaji, James Peter L., Marks Philip M.H., Chaddock John A., Acharya K. Ravi, Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A, Biochemical and Biophysical Research Communications, 381, 1, 2009. Crossref

  24. Yu Yun-Zhou, Zhang Shu-Ming, Ma Yao, Zhu Heng-Qi, Wang Wen-Bing, Du Yun, Zhou Xiao-Wei, Wang Rui-Lin, Wang Shuang, Yu Wei-Yuan, Huang Pei-Tang, Sun Zhi-Wei, Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F, Clinical Immunology, 137, 2, 2010. Crossref

  25. Liu Bo, Shi DanYang, Chang ShaoHong, Gong Xin, Yu YunZhou, Sun ZhiWei, Wu Jun, Characterization and immunological activity of different forms of recombinant secreted Hc of botulinum neurotoxin serotype B products expressed in yeast, Scientific Reports, 5, 1, 2015. Crossref

  26. Shearer Jeffry D., Manetz T. Scott, House Robert V., Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B), Vaccine, 30, 11, 2012. Crossref

  27. Ben David Alon, Torgeman Amram, Barnea Ada, Zichel Ran, Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate, Protein Expression and Purification, 110, 2015. Crossref

  28. Lu Shan, Wang Shixia, Technical transformation of biodefense vaccines, Vaccine, 27, 2009. Crossref

  29. Smith Leonard A., Botulism and vaccines for its prevention, Vaccine, 27, 2009. Crossref

  30. Montgomery Vicki A., Ahmed S. Ashraf, Olson Mark A., Mizanur Rahman M., Stafford Robert G., Roxas-Duncan Virginia I., Smith Leonard A., Ex vivo inhibition of Clostridium botulinum neurotoxin types B, C, E, and F by small molecular weight inhibitors, Toxicon, 98, 2015. Crossref

  31. Xie Xinmei, Wang Lin, Yang Wenliang, Yu Ruishuang, Li Qingli, Pang Xiaobin, Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency, Investigational New Drugs, 33, 4, 2015. Crossref

  32. Horowitz B Zane, Type E botulism, Clinical Toxicology, 48, 9, 2010. Crossref

  33. Zhang Jiu-Cong, Sun Li, Nie Qing-He, Botulism, where are we now?, Clinical Toxicology, 48, 9, 2010. Crossref

  34. Guo Jiubiao, Wang Jinglin, Gao Shan, Ji Bin, Waichi Chan Edward, Chen Sheng, Substrate-based inhibitors exhibiting excellent protective and therapeutic effects against Botulinum Neurotoxin A intoxication, Scientific Reports, 5, 1, 2015. Crossref

  35. Takahashi Tsuyoshi, Joshi Suresh G., Al-Saleem Fetweh, Ancharski Denise, Singh Ajay, Nasser Zidoon, Simpson Lance L., Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin, Vaccine, 27, 19, 2009. Crossref

  36. Yu Yun-Zhou, Zhang Shu-Ming, Wang Wen-Bing, Du Yun, Zhu Heng-Qi, Wang Rui-Lin, Zhou Xiao-Wei, Lin Jian-Bo, Wang Shuang, Yu Wei-Yuan, Huang Pei-Tang, Sun Zhi-Wei, Development and preclinical evaluation of a new F(ab′)2 antitoxin against botulinum neurotoxin serotype A, Biochimie, 92, 10, 2010. Crossref

  37. Webb Robert P., Smith Theresa J., Wright Patrick, Brown Jennifer, Smith Leonard A., Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3, Vaccine, 27, 33, 2009. Crossref

  38. Harrell William A., Vieira Rebecca C., Ensel Susan M., Montgomery Vicki, Guernieri Rebecca, Eccard Vanessa S., Campbell Yvette, Roxas-Duncan Virginia, Cardellina John H., Webb Robert P., Smith Leonard A., A matrix-focused structure-activity and binding site flexibility study of quinolinol inhibitors of botulinum neurotoxin serotype A, Bioorganic & Medicinal Chemistry Letters, 27, 3, 2017. Crossref

  39. Li Na, Yu Yun-Zhou, Yu Wei-Yuan, Sun Zhi-Wei, Enhancement of the immunogenicity of DNA replicon vaccine ofClostridium botulinumneurotoxin serotype A byGM-CSFgene adjuvant, Immunopharmacology and Immunotoxicology, 33, 1, 2011. Crossref

  40. Diamant Eran, Lachmi Bat-El, Keren Adi, Barnea Ada, Marcus Hadar, Cohen Shoshana, David Alon Ben, Zichel Ran, Goldman Ellen R., Evaluating the Synergistic Neutralizing Effect of Anti-Botulinum Oligoclonal Antibody Preparations, PLoS ONE, 9, 1, 2014. Crossref

  41. Yu Chi Ho, Song Dong Hyun, Choi Jun Young, Joe Hae Eun, Jeong Woo Hyeon, Hur Gyeung Haeng, Shin Young Kee, Jeong Seong Tae, A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication, Human Vaccines & Immunotherapeutics, 14, 2, 2018. Crossref

  42. Horowitz B. Zane, Botulism, in Critical Care Toxicology, 2017. Crossref

  43. Pittman Phillip R., Plotkin Stanley A., Biodefense and Special Pathogen Vaccines, in Plotkin's Vaccines, 2018. Crossref

  44. Horowitz B. Zane, Botulism, in Critical Care Toxicology, 2017. Crossref

  45. Clostridial Diseases, in Diseases of Poultry, 2013. Crossref

  46. Staats Herman F., Fielhauer Jeffrey R., Thompson Afton L., Tripp Alice A., Sobel Ashley E., Maddaloni Massimo, Abraham Soman N., Pascual David W., Deepe George, Mucosal Targeting of a BoNT/A Subunit Vaccine Adjuvanted with a Mast Cell Activator Enhances Induction of BoNT/A Neutralizing Antibodies in Rabbits, PLoS ONE, 6, 1, 2011. Crossref

  47. Ben David Alon, Diamant Eran, Barnea Ada, Rosen Osnat, Torgeman Amram, Zichel Ran, The Receptor Binding Domain of Botulinum Neurotoxin Serotype A (BoNT/A) Inhibits BoNT/A and BoNT/E Intoxications In Vivo , Clinical and Vaccine Immunology, 20, 8, 2013. Crossref

  48. Chellapandi P., Prisilla A., Clostridium botulinum type A-virulome-gut interactions: A systems biology insight, Human Microbiome Journal, 7-8, 2018. Crossref

  49. Khouri Jessica M., Motter Ruth N., Arnon Stephen S., Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity, Vaccine, 36, 15, 2018. Crossref

  50. Shi Dan-Yang, Chen Bo-Yang, Mao Yun-Yun, Zhou Guo, Lu Jian-Sheng, Yu Yun-Zhou, Zhou Xiao-Wei, Sun Zhi-Wei, Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B, Human Vaccines & Immunotherapeutics, 15, 3, 2019. Crossref

  51. Emanuel Andrew, Qiu Hongyu, Barker Douglas, Takla Teresa, Gillum Karen, Neimuth Nancy, Kodihalli Shantha, Gillet Daniel, Efficacy of equine botulism antitoxin in botulism poisoning in a guinea pig model, PLOS ONE, 14, 1, 2019. Crossref

  52. Shi Dan-Yang, Liu Fu-Jia, Mao Yun-Yun, Cui Rong-Tian, Lu Jian-Sheng, Yu Yun-Zhou, Dong Xiao-Jie, Yang Zhi-Xin, Sun Zhi-Wei, Pang Xiao-Bin, Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E, Human Vaccines & Immunotherapeutics, 16, 1, 2020. Crossref

  53. Boulianne Martine, Uzal Francisco A., Opengart Kenneth, Clostridial Diseases, in Diseases of Poultry, 2020. Crossref

  54. Horowitz B. Zane, Botulism, in Critical Care Toxicology, 2015. Crossref

  55. Adler Michael, Gul Nizamettin, Eitzen Edward, Oyler George, Molles Brian, Prevention and Treatment of Botulism, in Molecular Aspects of Botulinum Neurotoxin, 2014. Crossref

  56. Zichel R., Mimran A., Keren A., Barnea A., Steinberger-Levy I., Marcus D., Turgeman A., Reuveny S., Efficacy of a Potential Trivalent Vaccine Based on Hc Fragments of Botulinum Toxins A, B, and E Produced in a Cell-Free Expression System, Clinical and Vaccine Immunology, 17, 5, 2010. Crossref

  57. Held Daniel M., Shurtleff Amy C., Fields Scott, Green Christopher, Fong Julie, Jones Russell G. A., Sesardic Dorothea, Buelow Roland, Burke Rae Lyn, Vaccination of Rabbits with an Alkylated Toxoid Rapidly Elicits Potent Neutralizing Antibodies against Botulinum Neurotoxin Serotype B, Clinical and Vaccine Immunology, 17, 6, 2010. Crossref

  58. Sanford Daniel C., Barnewall Roy E., Vassar Michelle L., Niemuth Nancy, Metcalfe Karen, House Robert V., Henderson Ian, Shearer Jeffry D., Inhalational Botulism in Rhesus Macaques Exposed to Botulinum Neurotoxin Complex Serotypes A1 and B1, Clinical and Vaccine Immunology, 17, 9, 2010. Crossref

  59. Clapp Beata, Golden Sarah, Maddaloni Massimo, Staats Herman F, Pascual David W, Adenovirus F protein as a delivery vehicle for botulinum B, BMC Immunology, 11, 1, 2010. Crossref

  60. Sonkar Priyanka, Chauhan Vinita, Chauhan Ritika, Saxena Nandita, Dhaked Ram Kumar, Characterization of immune response induced against catalytic domain of botulinum neurotoxin type E, Scientific Reports, 10, 1, 2020. Crossref

  61. Xu Q, Pichichero M E, Simpson L L, Elias Md, Smith L A, Zeng M, An adenoviral vector-based mucosal vaccine is effective in protection against botulism, Gene Therapy, 16, 3, 2009. Crossref

  62. Przedpelski Amanda, Tepp William H., Kroken Abby R., Fu Zhuji, Kim Jung-Ja P., Johnson Eric A., Barbieri Joseph T., Bäumler A. J., Enhancing the Protective Immune Response against Botulism, Infection and Immunity, 81, 7, 2013. Crossref

  63. Mechaly Adva, Diamant Eran, Alcalay Ron, Ben David Alon, Dor Eyal, Torgeman Amram, Barnea Ada, Girshengorn Meni, Levin Lilach, Epstein Eyal, Tennenhouse Ariel, Fleishman Sarel J., Zichel Ran, Mazor Ohad, Highly Specific Monoclonal Antibody Targeting the Botulinum Neurotoxin Type E Exposed SNAP-25 Neoepitope, Antibodies, 11, 1, 2022. Crossref

  64. Ben David Alon, Papir Yoel, Hazan Ophir, Redelman Moses, Diamant Eran, Barnea Ada, Torgeman Amram, Zichel Ran, High Cell Density Cultivation Process for the Expression of Botulinum Neurotoxin a Receptor Binding Domain, Toxins, 14, 4, 2022. Crossref

  65. Sepulveda Jorge, Mukherjee Jean, Tzipori Saul, Simpson Lance L., Shoemaker Charles B., Efficient Serum Clearance of Botulinum Neurotoxin Achieved Using a Pool of Small Antitoxin Binding Agents, Infection and Immunity, 78, 2, 2010. Crossref

  66. Ben David Alon, Barnea Ada, Torgeman Amram, Diamant Eran, Dor Eyal, Schwartz Arieh, Rosen Osnat, Caspi Noa, Saraf Miki, Lerer Elad, Adar Yaakov, Lupo Edith, Toister Einat, Zichel Ran, Immunologic and Protective Properties of Subunit- vs. Whole Toxoid-Derived Anti-Botulinum Equine Antitoxin, Vaccines, 10, 9, 2022. Crossref

Próximos artigos

Identification of a novel five-gene prognostic model for laryngeal cancer associated with mitophagy using integrated bioinformatics analysis and experimental verification Dong Song, Lun Dong, Mei Wang, Xiaoping Gao Function of steroid receptor coactivators (SRCs) in T cells and cancers: Implications for cancer immunotherapy Wencan Zhang, Xu Cao, Hongmin Wu, Xiancai Zhong, Yun Shi, Zuoming Sun Electroacupuncture Alleviates Ischemic Stroke by Activating the mTOR/SREBP1 Pathway Jiawang Lang, Jianchang Luo, Luodan Wang, Wenbin Xu, Jie Jia, Zhipeng Zhao, Boxu Lang KIAA1429 induces the m6A modification of LINC01106 to enhance the malignancy of lung adenocarcinoma cell via JAK/STAT3 pathway Di Xu, Ziming Wang, Fajiu Li Effect of p-estrogen receptor at serine on its function and breast growth Yuan Liang, Junhui Qin, Tiancheng Ma, Tong Yang, Zhenyu Ke, Ruian Wang Mechanistic Insights into Tanshinone IIA in the Amelioration of Post-Thyroidectomy Hypoparathyroidism Xiaoyu Qian, Lin Li, Liang Chen, Chao Shen, Jian Tang MiRNA let-7d-5p alleviates inflammatory responses by targeting Map3k1 and inactivating ERK/p38 MAPK signaling in microglia Fan Fang, Cheng Chen Role of Natural Killer Cells as Cell-Based Immunotherapy in Oral Tumor Eradication and Differentiation Both In Vivo and In Vitro Kawaljit Kaur, Anahid Jewett The Current and Future States of Natural Killer Cell-Based Immunotherapy in Hepatocellular Carcinoma Tu Nguyen, Po-Chun Chen, Janet Pham, Kawaljit Kaur, Steven Raman, Anahid Jewett, Jason Chiang Phillygenin alleviated arthritis through the inhibition of NLRP3 inflammasome and Ferroptosis by AMPK Jianghui Wang, Shufang Ni, Kai Zheng, Yan Zhao, peihong zhang, Hong Chang The value of systemic immune-inflammation index and T cell subsets in the severity and prognosis of sepsis Hao Zhou Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach Muhammad Imran Qadir, Bilal Ahmed, Nadir Hussain Serum interleukin 6 and ferritin levels are the independent risk factors for pneumonia in elderly patients Hao Yuan, Jing Tian, Lu Wen Exploration of diagnostic markers associated with inflammation in chronic kidney disease (CKD) based on WGCNA and machine learning Qianjia Wu, Yang Yang, Chongze Lin Clinical significance of serum CTRP3 level in the prediction of cardiac dysfunction and intestinal mucosal barrier dysfunction in patients with severe acute pancreatitis Qiang Shao, Lin Sun The protective effect and mechanism of mild hypothermia on pig lung injury after cardiopulmonary resuscitation Jinlin Ren, Fangfang Zhu, Dongdong Sang, Mulin Cong, Shujuan Jiang Exploring mechanism of Zilongjin in treating lung adenocarcinoma based on network pharmacology combined with experimental verification Kang Zhang, Xiaoqun Chen Gastric Cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Genes Analysis Jian Shen, Minzhe Li Effects of different doses of dexmedetomidine on the prevention of postoperative sleep disturbance and serum neurotransmitter level in patients under general anesthesia Huifei Lu, Fei He, Ying Huang, Zhongliang Wei Identification of key ubiquitination-related genes and their associated with immune infiltration in osteoarthritis based on mRNA-miRNA network Dalu Yuan, Hailiang Shen, Lina Bai, Menglin Li, Qiujie Ye Diagnostic and Prognostic value of peripheral neutrophil CD64 index in elderly patients with community-acquired pneumonia Yan Li, Jing Zhang, Suhang Wang, Jie Cao Identification of Metabolism-Related Prognostic Biomarkers and Immune Features of Head and Neck Squamous Cell Carcinoma Rongjin Zhou, Junguo Wang Downregulation of miR-503-5p promotes the development of pancreatic cancer via targeting cyclin E2 Fei Li, Ying-pei Ling, Pan Wang, Shi-cheng Gu, Hao Jiang, Jie Zhu
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain